Gilead completes acquisition of Kite Pharma

Gilead Sciences has completed the acquisition of Kite Pharma and is proud to officially welcome Kite’s more than 700 talented employees to the Gilead organization – for further details on the acquisition, click here.

Over the past 30 years, Gilead has made significant advances that have improved the lives of people living with HIV and, over the past four years, has introduced four medicines that offer a cure for chronic hepatitis C virus.

With the addition of Kite’s CAR T and TCR cellular therapy platforms, we believe that together we can bring that same kind of innovation to cancer. For more information on cell therapy and Kite Pharma, see www.kitepharma.com